Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

LNS for MPS IVA

1H11: Availability of blood Phe monitor

Research and Development Programs

BioMarin continues to make significant investments in research and development to ensure continued growth of the company. The current pipeline includes programs which are in various stages of development and are focused on treating a range of unmet medical needs. BioMarin is making significant investments in manufacturing and laboratory facilities to support the advancement of these programs.

  • GALNS for MPS IVA: BioMarin initiated the Phase I/II trial in mid-April 2009 and completed enrollment in mid-July. The Phase I/II study is a 36-week, open-label, within-patient dose escalation trial followed by a treatment continuation phase. The company expects to report initial results in the first half of 2010. Assuming positive results from the Phase I/II study, BioMarin expects to initiate a pivotal Phase III study in late 2010 or early 2011.
  • PEG-PAL for PKU: BioMarin initiated the Phase II trial in September 2009. The Phase II clinical trial is an open-label, multi-center study to be conducted in up to 35 patients in a series of dose-escalating cohorts. The primary treatment period of eight once weekly injections at a fixed dose will be followed by eight weeks of dose and frequency optimization and an extension period. Results from the Phase II PEG-PAL trial are expected in mid-2010.
  • BMN-195 - Utrophin upregulator for Duchenne Muscular Dystrophy: BioMarin is in the final stages of preparing the regulatory filing and expects to initiate a Phase I trial by the first quarter of 2010. BMN-195 is an orally available small molecule which may upregulate utrophin, a potential substitution for the missing dystrophin protein in DMD patients.
  • Kuvan lifecycle development: Several programs are underway to expand and protect the market and to improve the ability of healthcare
    '/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Mass., Dec. 16 Boston Scientific Corporation (NYSE: ... Board of Directors has elected Nelda Connors as a ... of the Electrical and Metal Products division of Tyco ... Eaton Corporation, holding several positions in operations and general ... in a number of executive and management capacities with ...
(Date:12/16/2009)... Siemens Healthcare today announced a series ... to help healthcare providers pursue meaningful ... the HITECH provision of the American Recovery ... zero-percent interest terms for qualified customers, the ... associated with their technology investment while meeting ...
(Date:12/16/2009)... 16 BioSpecifics Technologies Corp. (Nasdaq: ... class collagenase-based products, today announced top-line efficacy and ... of XIAFLEX(TM) for the treatment of Peyronie,s disease. ... inelastic collagen on the shaft of the penis, ... intercourse difficult or impossible in advanced cases. The ...
Breaking Medicine Technology:Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 1CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 2CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 3CBS and OMD Partner to Provide the Agency With Access to the Networks Television City Research Facility in Las Vegas 10669 4Wet ethanol production process yields more ethanol and more co products 10667 1Wet ethanol production process yields more ethanol and more co products 10667 2Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 60993 1Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 60993 2
... DuoCort AB,today announced that results of the Phase ... dual release hydrocortisone tablets for adrenal insufficiency,will be ... on,April 30 in Budapest. The trial evaluated the ... healthy,volunteers., The Phase I study showed that both ...
... BioDelivery,Sciences International, Inc. (Nasdaq: BDSI) announced today,statistically ... with breakthrough pain in its pivotal Phase ... results are based on,achievement of the primary ... Intensity Difference (SPID), compared to placebo., The ...
Other Medicine Technology:DuoCort AB: DuoCort announces Phase I Data Presentation at the,European Congress of Endocrinology 2BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 2BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 3BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 4BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 5BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 6
(Date:12/16/2009)... Institute will sponsor a new learning collaborative ... who serve individuals at risk of, or ... plan, medical home and other provider settings. ... webinars on topics, solutions and case studies ... improvement. Each webinar will include a brief ...
(Date:12/16/2009)... teams led by the Wellcome Trust Sanger Institute announce ... All cancers are caused by mutations in the DNA ... lifetime. The studies, of a malignant melanoma and a ... the mutations in the genomes of two cancers. , ... year: almost all are associated with smoking. The number ...
(Date:12/16/2009)... New Immune-boosting, Newborn-Safe Skin Care Products from Episencial Offers Planet-Friendly ... Now Available , ... Los Angeles, ... green values now have an authentic, affordable choice in all ... launches its eponymous product line for young children featuring ...
(Date:12/16/2009)... Paper technology and the provider of the optimal paper-based e-data ... ranked among the Fastest Growing Technology Companies on the Deloitte ... ... (PRWEB) December 16, 2009 -- Kayentis ... management of handwritten data. Kayentis targets the Healthcare and Life ...
(Date:12/16/2009)... uninsured, government report finds , , WEDNESDAY, Dec. 16 (HealthDay ... year, 45.4 million Americans of all ages -- or ... insurance, according to new National Health Interview Survey statistics ... people of all ages had been uninsured for at ... and 31.9 million (10.6 percent) had been uninsured for ...
Breaking Medicine News(10 mins):Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News:Over 45 Million Americans Now Lack Health Insurance 2
... We have previously shown that E2 and P4 have ... epithelial changes during early H. pylori infection. Recently, Ohtani ... administration in H. pylori-infected InGas mice. Other studies have ... murine gastric mucosa. ER and PR have been reported in ...
... Connections,Between Pay and Performance and Streamlines Talent ... Salary.com, Inc.,(Nasdaq: SLRY ), a ... solutions, today announced that Pacira Pharmaceuticals, an ... Parsippany, New,Jersey and La Jolla and San ...
... Oct. 31 Thousands of,people will be able to ... held at or near polling sites across the United ... & Vax project, a non-partisan and,non-political public health effort ... are taking place in 41 states plus the District ...
... Team up to Help Local Children,s Hospitals Across the ... ... year,Aflac will introduce a new plush duck for the holidays. The Aflac Holiday,Duck ... http://www.aflacholidayduck.com . Proceeds from,the sale of the Holiday Duck go toward ...
... out excess calcium, study finds , , FRIDAY, Oct. 31 (HealthDay ... loss in humans has been identified by European researchers. , ... called Oblivion had problems with the function of hair cells ... of the Oblivion gene, ear hair cells showed some initial ...
... an exaggerated intestinal immune response to otherwise innocuous ... plays a key role in the pathophysiology of ... yet emerged. Vitamin E is a major lipophilic ... which protects membrane lipids from peroxidation by scavenging ...
Other Medicine News:Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 2Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 3Health News:Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes 2Health News:Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes 3Health News:Vote & Vax Flu Shot Clinics Operating at More Than 250 Polling Sites Nationwide 2Health News:Aflac Duck Gives Back 2Health News:Aflac Duck Gives Back 3Health News:Mutant Mouse Gene Offers Clues to Hearing Loss 2Health News:Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis? 2
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
DarcoGel™ Upper chamber is foam filled, conforms to calf; gel-filled lower chamber molds to the malleoli for a custom fit. Freeze the removable liner for cold therapy. One size. Fits left or ri...
Compression Ankle Support Four-way ankle compression support with reinforced triangular closed-heel design for comfort, mobility and longer wear. Reduces swelling and does not retain heat or moisture...
... combines the clinically proven Air-Stirrup Ankle ... addition, a comprehensive instruction booklet is ... provides information on treatment and rehabilitation ... management.,Each Air-Stirrup Ankle Brace features anatomically ...
Medicine Products: